InflaRx (NASDAQ:IFRX) Given New $10.00 Price Target at Guggenheim

InflaRx (NASDAQ:IFRX) had its price target lifted by equities research analysts at Guggenheim from $7.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of InflaRx in a research report on Friday, March 21st.

InflaRx Stock Performance

NASDAQ:IFRX opened at $1.32 on Wednesday. InflaRx has a 52 week low of $1.13 and a 52 week high of $2.82. The stock’s 50 day moving average price is $1.90 and its 200 day moving average price is $1.90. The company has a market capitalization of $88.55 million, a P/E ratio of -1.23 and a beta of 1.98.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. As a group, sell-side analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Large investors have recently bought and sold shares of the company. Two Sigma Securities LLC bought a new position in InflaRx during the 4th quarter worth about $28,000. Walleye Capital LLC acquired a new position in shares of InflaRx in the fourth quarter valued at $51,000. Cubist Systematic Strategies LLC acquired a new stake in InflaRx during the 4th quarter worth approximately $55,000. Geode Capital Management LLC boosted its holdings in InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after purchasing an additional 11,900 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after acquiring an additional 19,000 shares during the period. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.